Buformin Concentrations in a Case of Fatal Lactic Acidosis

Overview

Journal Diabetologia

Specialty Endocrinology

Date 1981 Jan 1

PMID 7202882

Citations 1

Authors

L F Verdonck

B Sangster

A N van Heijst

G de Groot

R A Maes

Affiliations

Soon will be listed here.

Abstract

A fatal case of lactic acidosis in a 84 year old diabetic woman taking buformin is reported. Buformin concentrations in serum, other body fluids and tissues were measured by gas chromatography. Serum buformin concentration at admission was 5.5 mg/l. Postmortem concentrations were: in serum 3.2 mg/l; in lung 2.8 mg/kg wet weight; in heart 3.0 mg/kg; in pericardial fluid 3.5 mg/l; in liver 5.2 mg/kg; in bile 6.3 mg/l; and in kidney 98 mg/kg.

Citing Articles

Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Marchetti P, Navalesi R Clin Pharmacokinet. 1989; 16(2):100-28.

PMID: 2656043 DOI: 10.2165/00003088-198916020-00004.

References

Ng M, LEVY M, Zieske H . Effects of changes of pH and of carbon dioxide tension on left ventricular performance. Am J Physiol. 1967; 213(1):115-20. DOI: 10.1152/ajplegacy.1967.213.1.115. View

Zahringer J, Cyran J, Luderitz B . [Lactacidosis in biguanide therapy: diagnosis and therapy. 4 cases compared to 179 cases in the world literature]. Schweiz Med Wochenschr. 1978; 108(47):1838-46. View

Alberti K, Nattrass M . Lactic acidosis. Lancet. 1977; 2(8027):25-9. DOI: 10.1016/s0140-6736(77)90015-0. View

LINTZ W, Berger W, Aenishaenslin W, Kutova V, Baerlocher C, Kapp J . Butylbiguanide concentration in plasma, liver, and intestine after intravenous and oral administration to man. Eur J Clin Pharmacol. 1974; 7(6):433-48. DOI: 10.1007/BF00560356. View

Deppermann D, Heidland A, Ritz E, Horl W . [Lactic acidosis--a possible complication in buformin-treated diabetics (author's transl)]. Klin Wochenschr. 1978; 56(17):843-53. DOI: 10.1007/BF01479834. View

Wildenthal K, Mierzwiak D, Myers R, Mitchell J . Effects of acute lactic acidosis on left ventricular performance. Am J Physiol. 1968; 214(6):1352-9. DOI: 10.1152/ajplegacy.1968.214.6.1352. View

Irsigler K, Kritz H, Regal H, Foltin E . [The risk of lacticate acidosis: a comparison of the 3 biguanides in treatment of diabetics (authors' transl)]. Wien Klin Wochenschr. 1978; 90(10):332-7. View

Bottermann P, Schweigart U, Ermler R . [Investigations of the mode action of buformin using a 3H-labelled glucose in people with a healthy metabolism (author's transl)]. Med Klin. 1976; 71(36):1423-8. View

Beckmann R, LINTZ W . Evaluation of a sustained release form of the oral antidiabetic butylbiguanide (Silubin retard). Eur J Clin Pharmacol. 1971; 3(4):221-8. DOI: 10.1007/BF00565010. View

10.

Berger W, MULLY K, Heierli C, Ritz R . [10 cases of lactic acidosis during biguanide therapy (buformin and phenformin)]. Schweiz Med Wochenschr. 1976; 106(50):1830-4. View

11.

Losert W, KOLB K, Bitterling G . [Distribution of 1-butyl-biguanide- 14 C in rats and guinea pigs]. Arzneimittelforschung. 1972; 22(5):937-46. View

12.

Althoff P, Fassbinder W, Neubauer M, Koch K, SCHOFFLING K . [Haemodialysis in the treatment of biguanide-induced lactate acidosis (author's transl)]. Dtsch Med Wochenschr. 1978; 103(2):61-8. DOI: 10.1055/s-0028-1104382. View

13.

Luft D, Schmulling R, EGGSTEIN M . Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia. 1978; 14(2):75-87. DOI: 10.1007/BF01263444. View